VivoSeq
Metabolic & Endocrine

Non-Alcoholic Steatohepatitis

86

Pipeline Programs↗

13

Active Trials↗

49

Companies Involved↗

Non-Alcoholic Steatohepatitis is a moderately active landscape with 86 programs across 49 companies. The most active players are Galectin Therapeutics Inc., GSK, Dexcel Pharma Technologies Ltd.. 16 therapies are approved with 6 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

68/100

Pipeline Velocity

11/100

Mech. Concentration

6/100

Completion Rate

83/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

G

Galectin Therapeutics Inc.

1 program

Phase 1GSK logo

GSK

1 program

Phase 1D

Dexcel Pharma Technologies Ltd.

1 program

Phase 1EMD Serono logo

EMD Serono

1 program

Phase 1Bristol-Myers Squibb logo

Bristol-Myers Squibb

2 programs

Phase 2Gilead logo

Gilead

2 programs

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

92%

Small molecule

86 of 93 classified programs — the dominant modality here.

8%ALL OTHERSPeptide55%Protein / enzyme11%Radiopharmaceutical11%

Small molecule leads; the ring shows all 93 classified programs, each share of the total. Modality classified for 98% of 97 pipeline programs.

Analysis

Trial Status

85

clinical trials

Completed53 · 62%
Unknown status8 · 9%
Terminated8 · 9%
Recruiting8 · 9%
Active, not recruiting3 · 4%
Withdrawn3 · 4%
Other2 · 2%

Clinical Trials

Trial Activity

85 trials

Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjects With Non-alcoholic Steatohepatitis (NASH)
Recruiting·CChia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.·Phase 2·NCT06569524·120 enrolled
Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH)
Recruiting·CCan-Fite BioPharma·Phase 2·NCT04697810·114 enrolled
Trial of CS060380 Tablets for Non-alcoholic Steatohepatitis (NASH)
Recruiting·CCascade Pharmaceuticals, Inc·Phase 2·NCT07198386·120 enrolled
A Study of INI-822 in Healthy Volunteers and Participants with Non-alcoholic Steatohepatitis (NASH) or Presumed NASH
Recruiting·IInipharm Australia Pty Ltd·Phase 1·NCT05945537·104 enrolled
A Multicenter, Double-blind, Placebo-randomized Controlled Clinical Study on the Treatment of Non-alcoholic Steatohepatitis With Tibetan Drug Langqing Atar
Recruiting·—·N/A·NCT06193629·150 enrolled
Clinical Study Evaluating the Safety and Efficacy of Esomeprazole in Treatment of Non-alcoholic Steatohepatitis
Recruiting·SSadat City University·Phase 1/2·NCT06302049·46 enrolled
Non-Alcoholic Fatty Liver Disease, the Hepatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
Recruiting·National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT03884075·104 enrolled
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Recruiting·Akero Therapeutics logoAkero Therapeutics·Phase 3·NCT06215716·1,650 enrolled
Comparative Study Between Febuxostat Versus Vitamin E in Non-alcoholic Steatohepatitis Patients With Hyperuricemia
Active, not recruiting·TTanta University·Phase 2·NCT05574036·70 enrolled
Comparative Study Between Obeticholic Acid Versus Vitamin E in Patients with Non-alcoholic Steatohepatitis
Active, not recruiting·TTanta University·Phase 2·NCT05573204·59 enrolled
The Effect of Semaglutide in Subjects With Non-cirrhotic Non-alcoholic Steatohepatitis
Active, not recruiting·Novo Nordisk logoNovo Nordisk·Phase 3·NCT04822181·1,205 enrolled
A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of SNP-610 for the Treatment of Patients With Non-alcoholic Steatohepatitis
Not yet recruiting·SSinew Pharma Inc.·Phase 2·NCT03468556·80 enrolled
Reducing Non-Alcoholic Steatohepatitis
Enrolling by invitation·MMilitary University Hospital, Prague·N/A·NCT06519448·30 enrolled
Safety, Tolerability, Pharmacokinetics and Activity of GS-9450 in Adults With Non-Alcoholic Steatohepatitis (NASH)
Completed·Gilead logoGilead·Phase 2·NCT00740610·124 enrolled
Effect of Dipeptidyl Peptidase- 4 Inhibitors on Non-Alcoholic Steatohepatitis and Type 1 Diabetes
Completed·—·Phase 3·NCT06348706·60 enrolled
Page 1 of 6

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)